Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks.

Mayo Clinic proceedings - 1 Oct 2016

Singh Mandeep, Bhatt Deepak L, Stone Gregg W, Rihal Charanjit S, Gersh Bernard J, Lennon Ryan J, Narula Jagat, Fuster Valentin

Abstract excerpt

It is estimated that in the United States, each year, approximately 620,000 persons will experience an acute coronary syndrome and approximately 70% of these will have non-ST-elevation acute coronary syndrome. Cardiovascular disease still accounts for 1 of every 3 deaths in the United States, and there is an urgent need to improve the prognosis of patients presenting with acute coronary syndrome. Cardiovascular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Adenosine Monophosphate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antithrombins

Share to Fibrinolytic Agents

Share to Platelet Glycoprotein GPIIb-IIIa Complex

Share to Prasugrel Hydrochloride

Share to Purinergic P2Y Receptor Antagonists

Share to Ticagrelor

Source

Identifiers

PMID: 27712639
DOI: 10.1016/j.mayocp.2016.06.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks.PMID 27712639Read ↗

What is the optimal antithrombotic strategy in primary percutaneous coronary intervention?Semantic proximity Read ↗

Changes of antithrombotic prescription in atrial fibrillation patients with acute coronary syndrome or percutaneous coronary intervention and the subsequent impact on long-term outcomes: A longitudinal cohort studySemantic proximity Read ↗

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve ImplantationSemantic proximity Read ↗

Safety considerations with the use of platelet inhibitors for elderly patients with non-ST- elevation acute coronary syndrome.Semantic proximity Read ↗

Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?Semantic proximity Read ↗

Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.Semantic proximity Read ↗

Ticagrelor versus clopidogrel in acute coronary syndrome patients with concurrent high ischemic and bleeding risk after drug-eluting stent implantationSemantic proximity Read ↗

Initial ticagrelor monotherapy strategy is effective and safe in patient with high bleeding risk after percutaneous coronary intervention: series case reports and literature reviewSemantic proximity Read ↗

Antithrombotic Therapy in Atrial Fibrillation Patients with Prior Complex Percutaneous Coronary Intervention: A Secondary Analysis of the Randomized ADAPT AF-DES TrialSemantic proximity Read ↗

Utilization of Triple Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary InterventionSemantic proximity Read ↗

Cardiovascular pharmacogenetics of anti-thrombotic agents and non-steroidal anti-inflammatory drugs.Semantic proximity Read ↗

North American Thrombosis Forum, AF Action Initiative Consensus Document.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.